RU2012147319A - POLYCYCLIC QUINAZOLES, THEIR PRODUCTION AND APPLICATION - Google Patents
POLYCYCLIC QUINAZOLES, THEIR PRODUCTION AND APPLICATION Download PDFInfo
- Publication number
- RU2012147319A RU2012147319A RU2012147319/04A RU2012147319A RU2012147319A RU 2012147319 A RU2012147319 A RU 2012147319A RU 2012147319/04 A RU2012147319/04 A RU 2012147319/04A RU 2012147319 A RU2012147319 A RU 2012147319A RU 2012147319 A RU2012147319 A RU 2012147319A
- Authority
- RU
- Russia
- Prior art keywords
- quinazolino
- quinazoline
- substituted
- methoxyethoxy
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1. По меньшей мере один активный фармацевтический ингредиент, выбранный из полициклических хиназолинов формулы V,их фармацевтически приемлемых солей и гидратов фармацевтически приемлемых солей, где Rи Rнезависимо выбраны из водорода, галогена, амино, нитро, гидроксамино, карбоксила, C-Cалкоксикарбонила, C-Cалкила, C-Cациламино, (E)-4-(диметиламино)-2-бутенациламино, алкокси, гуанидино, уреидо, трифторметила, C-Cсульфонила, арилсульфонила, замещенного и незамещенного фенила, замещенного и незамещенного гетероцикла;Rи Rнезависимо выбраны из водорода, галогена, трифторметила, циано, C-Cалкинила, нитро, амино, гидроксила, метилола, сложного алкильного эфира сульфокислоты, C-Cалкила, C-Cалкокси, C-Cациламино, бензамидо, C-Cзамещенного амино, C-Cненасыщенной алифатической цепи, замещенного и незамещенного пятичленного алифатического кольца, замещенного и незамещенного шестичленного алифатического кольца, замещенного и незамещенного фенила, замещенного гетероцикла, замещенного бензилокси;Rвыбран из водорода, трифторметила, C-Cалкила и C-Cалкокси;R, R, R, Rи Rодновременно не являются водородом.2. По меньшей мере один активный фармацевтический ингредиент по п.1, отличающийся тем, что замещенный фенил содержит от 1 до 4 заместителей, независимо выбранных из галогена, гидроксила, нитро, циано, C-Cалкокси, C-Cалкила и амино.3. По меньшей мере один активный фармацевтический ингредиент по п.1, отличающийся тем, что гетероцикл представляет собой насыщенное или ненасыщенное пяти- или шестичленное кольцо, содержащее по меньшей мере один гетероатом, выбранный из N, О и S.4. По меньшей мере один активный фармацевтический ингредиент по п.2, отличающийся тем, 1. At least one active pharmaceutical ingredient selected from polycyclic quinazolines of formula V, their pharmaceutically acceptable salts and hydrates of pharmaceutically acceptable salts, where R and R are independently selected from hydrogen, halogen, amino, nitro, hydroxamino, carboxyl, C-alkoxycarbonyl, C- C1-6 alkyl, C-Cacylamino, (E) -4- (dimethylamino) -2-butenacylamino, alkoxy, guanidino, ureido, trifluoromethyl, C-Csulfonyl, arylsulfonyl, substituted and unsubstituted phenyl, substituted and unsubstituted heterocycles; R and R are independently , halogen, trifluoromethyl, cyano, C-Calkynyl, nitro, amino, hydroxyl, methylol, sulfonic acid alkyl ester, C-Calkyl, C-Calkoxy, C-Cacylamino, benzamido, C-C substituted amino, C-C unsaturated aliphatic chain, substituted and unsubstituted five-membered aliphatic ring, substituted and unsubstituted six-membered aliphatic ring, substituted and unsubstituted phenyl, substituted heterocycle, substituted benzyloxy; R is selected from hydrogen, trifluoromethyl, C-Calkyl and C-Calkoxy; R, R, R, R and R are not hydrogen at the same time. 2. At least one active pharmaceutical ingredient according to claim 1, characterized in that the substituted phenyl contains from 1 to 4 substituents independently selected from halogen, hydroxyl, nitro, cyano, C-alkoxy, C-Calkyl and amino. At least one active pharmaceutical ingredient according to claim 1, characterized in that the heterocycle is a saturated or unsaturated five- or six-membered ring containing at least one heteroatom selected from N, O and S.4. At least one active pharmaceutical ingredient according to claim 2, characterized in
Claims (34)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010182895 | 2010-05-21 | ||
CN201010182895.7 | 2010-05-21 | ||
PCT/CN2011/074434 WO2011144059A1 (en) | 2010-05-21 | 2011-05-20 | Fused quinazoline derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2012147319A true RU2012147319A (en) | 2014-06-27 |
Family
ID=44972984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012147319/04A RU2012147319A (en) | 2010-05-21 | 2011-05-20 | POLYCYCLIC QUINAZOLES, THEIR PRODUCTION AND APPLICATION |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110288086A1 (en) |
EP (1) | EP2592083A4 (en) |
JP (1) | JP2013526590A (en) |
KR (1) | KR20130045275A (en) |
CN (1) | CN102918044A (en) |
AU (1) | AU2011255169A1 (en) |
BR (1) | BR112012028964A2 (en) |
CA (1) | CA2799989A1 (en) |
MX (1) | MX2012013527A (en) |
RU (1) | RU2012147319A (en) |
WO (1) | WO2011144059A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013159698A1 (en) * | 2012-04-26 | 2013-10-31 | 深圳信立泰药业股份有限公司 | Fused ring quinazoline hydroximic acid compound and use thereof as anti-tumour drug |
CN106518879B (en) * | 2016-09-21 | 2018-12-07 | 西安交通大学 | A kind of 2,3- lactam nucleus condenses quinazoline -4 (3H) -one derivative and its preparation method and application |
CN106928069B (en) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | A kind of preparation method of 4,5- bis- (2- methoxy ethoxy) -2- ethyl nitrobenzoate |
CN108358798A (en) * | 2018-02-12 | 2018-08-03 | 黑龙江鑫创生物科技开发有限公司 | A kind of method of micro passage reaction synthesis Tarceva intermediate |
CN113603650B (en) * | 2021-08-03 | 2023-03-10 | 杭州职业技术学院 | Catalytic cyclization preparation method and application of erlotinib key intermediate |
TW202315625A (en) * | 2021-08-13 | 2023-04-16 | 大陸商深圳信立泰藥業股份有限公司 | Terpyridine diketone compound or salt thereof, preparation method therefor and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
PL332416A1 (en) * | 1996-09-23 | 1999-09-13 | Rutgers | Substituted heterocyclic compounds as anticarcinogenic agents |
US7262297B2 (en) * | 2003-05-15 | 2007-08-28 | Hoffmann-La Roche Inc. | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
KR100843053B1 (en) | 2004-01-16 | 2008-07-01 | 에프. 호프만-라 로슈 아게 | 1-benzyl-5-piperazin-1-yl-3,4-dihydro-1h- quinazolin-2-one derivatives and the respective 1h-benzo1,2,6thiadiazine-2,2-dioxide and 1,4-dihydro-benzod 1,3oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor5-ht for the treatment of diseases of the central nervous system |
GB0601215D0 (en) | 2006-01-21 | 2006-03-01 | Astrazeneca Ab | Chemical compounds |
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
CN101457251A (en) * | 2007-12-10 | 2009-06-17 | 浙江大学 | Screen method of sensitization tumour cell pharmaceutical product and use thereof |
CN101613356B (en) * | 2009-07-23 | 2012-07-04 | 东南大学 | Quinazoline tetracyclic derivative, preparation method thereof and application thereof in pharmacy |
-
2011
- 2011-05-20 CA CA2799989A patent/CA2799989A1/en not_active Abandoned
- 2011-05-20 US US13/112,354 patent/US20110288086A1/en not_active Abandoned
- 2011-05-20 WO PCT/CN2011/074434 patent/WO2011144059A1/en active Application Filing
- 2011-05-20 CN CN2011800261684A patent/CN102918044A/en active Pending
- 2011-05-20 EP EP11782976.2A patent/EP2592083A4/en not_active Withdrawn
- 2011-05-20 AU AU2011255169A patent/AU2011255169A1/en not_active Abandoned
- 2011-05-20 KR KR1020127033456A patent/KR20130045275A/en not_active Application Discontinuation
- 2011-05-20 BR BR112012028964A patent/BR112012028964A2/en not_active IP Right Cessation
- 2011-05-20 RU RU2012147319/04A patent/RU2012147319A/en not_active Application Discontinuation
- 2011-05-20 MX MX2012013527A patent/MX2012013527A/en not_active Application Discontinuation
- 2011-05-20 JP JP2013511520A patent/JP2013526590A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20110288086A1 (en) | 2011-11-24 |
CA2799989A1 (en) | 2011-11-24 |
BR112012028964A2 (en) | 2016-07-26 |
CN102918044A (en) | 2013-02-06 |
WO2011144059A1 (en) | 2011-11-24 |
JP2013526590A (en) | 2013-06-24 |
EP2592083A4 (en) | 2014-01-22 |
KR20130045275A (en) | 2013-05-03 |
MX2012013527A (en) | 2013-04-08 |
EP2592083A1 (en) | 2013-05-15 |
AU2011255169A1 (en) | 2013-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012147319A (en) | POLYCYCLIC QUINAZOLES, THEIR PRODUCTION AND APPLICATION | |
ES2466818T3 (en) | C-Met modulators and methods of use | |
ES2452868T3 (en) | New histone deacetylase inhibitors based simultaneously on 1H-trisubstituted pyrroles and aromatic and heteroaromatic spacers | |
CN112390796B (en) | KRAS G12C inhibitor and application thereof in medicine | |
RU2010131833A (en) | METHODS FOR PRODUCING CHINAZOLINONE DERIVATIVES | |
RU2005117341A (en) | Pyrimidine Compounds with Antiproliferative Activity (II) | |
JP7340574B2 (en) | Flabagrin derivatives | |
JP2009514947A (en) | Quinazoline derivatives as multiple inhibitors and process for producing the same | |
JP2005529076A (en) | Synthesis of quinazolinone | |
TWI771342B (en) | Preparation method for pyrrole six-membered heteroaryl ring derivative and intermediate thereof | |
CA2989722A1 (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
TW201240970A (en) | Pyrazole compounds and thiazole compounds as protein kinases inhibitors | |
ZA200600107B (en) | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo [2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | |
BR112015017963A2 (en) | deuterated phenyl amino pyrimidine compound, method for preparing the pharmaceutical composition, pharmaceutical composition and use of the compound | |
WO2017143842A1 (en) | Substituted diaminopyrimidine compound and composition comprising same and use thereof | |
JP2002167387A (en) | 2-(7,8-dihydro-8-oxo-9h-purine-9-yl)aceticacid derivative | |
JP2002088073A (en) | Anti-androgenic agent | |
EP3181553A1 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
RU2361855C2 (en) | Aminobenzophenones | |
ES2348360T3 (en) | BENCIMIDAZOL DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS. | |
JP2019519534A (en) | Five-membered heterocyclic [3,4-d] pyridazinone compounds, method for producing the same, pharmaceutical composition and application | |
ES2833473T3 (en) | Purinyl-N-hydroxyl pyrimidine formamide derivatives, method of preparation and use thereof | |
IL199422A (en) | O-substituted-dibenzyl urea-derivatives as trpv1 receptor antagonists | |
CN113365615A (en) | Compounds for inhibiting unregulated cell growth | |
US20130296348A1 (en) | Bis-Quinazoline Derivatives as Inhibitors for Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141113 |